UFP Technologies Q2 Revenue Jumps 15%, Crushing Estimates on MedTech Strength
UFPT sits 54% above its 52-week low of $173.86.
Summary
UFP Technologies delivered a standout Q2, with revenue surging 15% to $174 million, well above the $159 million consensus. Adjusted EPS climbed to $2.92 from $2.50 a year ago, driven by broad-based strength in the MedTech segment—both top-five customers and the rest of the business posted strong gains. The company is investing heavily in Dominican Republic operations to support growth, though this is creating near-term margin pressure in U.S. facilities. The stock, trading near its 52-week high, now commands a higher forward P/E of 23x versus 19x three months ago, reflecting raised expectations. With a new CEO in place since June and a buy-rated consensus, the focus shifts to whether the Dominican investments can sustain this momentum without further margin erosion.
At the time of this announcement, UFPT was trading at $267.53 on NASDAQ in the Life Sciences sector, with a market capitalization of approximately $2.1B. The 52-week trading range was $173.86 to $279.49. This news item was assessed with positive market sentiment and an importance score of 8 out of 10. Source: Reuters.